U.S. High Court Won’t Rule If Drug Maker Has Duty To Monitor Drug Study Patients

(October 1, 2018, 12:00 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on Oct. 1 said it will not review a California state appeals court ruling that overturned a $5.6 million Risperdal death verdict, preserving a...
To view the full article, register now.